Effectiveness and safety of lenvatinib plus anti‐programmed death‐1 antibodies in patients with hepatocellular carcinoma: A real‐world cohort study

OBJECTIVE: Lenvatinib plus anti‐programmed death‐1 (anti‐PD‐1) antibody combinations have shown potent anti‐tumor effect in phase I/II trials in advanced or unresectable hepatocellular carcinoma (HCC), but real‐world data are limited. METHODS: To investigate the effectiveness and safety of lenvatini...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Ming‐Hao, Huang, Cheng, Li, Mei‐Ling, Zhu, Xiao‐Dong, Tan, Chang‐Jun, Zhou, Jian, Fan, Jia, Sun, Hui‐Chuan, Shen, Ying‐Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166966/
https://www.ncbi.nlm.nih.gov/pubmed/36790032
http://dx.doi.org/10.1002/cam4.5661

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166966/
https://www.ncbi.nlm.nih.gov/pubmed/36790032
http://dx.doi.org/10.1002/cam4.5661

Ejemplares similares